Shopping Cart 0
Cart Subtotal
AED 0

Medical University of Vienna - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Medical University of Vienna (MUV) is a medical research institute that offers educational services. The institute provides research and education services in the field of medical science. Its research services include project submission, clinical and preclinical studies, research funding, biobank and medical engineering, patenting, research documentation and others. MUV's courses include clinical research, gender medicine, health care management, interdisciplinary pain medicine, medical hypnosis, periodontology, toxicology, and dental hypnosis, among others. The institute's outpatient services include immunization services, genetic counseling, donation of bodies to research, forensic medicine, and others. It provides medical research in allergology, immunology, infectiology, oncology, neuroscience and psychiatric-psychosocial science, vacular medicine, and bildgebung. MUV is headquartered in Vienna, Austria.

Medical University of Vienna-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Medical University of Vienna, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Medical University of Vienna, Medical Devices Deals, 2012 to YTD 2018 10

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Medical University of Vienna, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Cyxone Partners with Medical University of Vienna 12

Imugene Enters Into Partnership with Medical University of Vienna 13

Licensing Agreements 14

APEIRON Biologics Enters into Licensing Agreement with Molecular Biotechnology and Medical University of Vienna 14

MedUni Vienna Enters into Licensing Agreement with Accequa 15

Asset Transactions 16

Cyxone to Acquire T20K Patent Portfolio from Medical University of Vienna 16

Cyxone Acquires Cyclotide Patent Rights from MedUni Vienna and University Medical Center Freiburg 17

Medical University of Vienna-Key Competitors 18

Medical University of Vienna-Key Employees 19

Medical University of Vienna-Locations And Subsidiaries 20

Head Office 20

Other Locations & Subsidiaries 20

Recent Developments 21

Strategy And Business Planning 21

Oct 19, 2017: Fresenius Vamed opens Institute for Gender Medicine 21

Government and Public Interest 22

Aug 28, 2018: Epigenetic analysis of aggressive brain tumors 22

Jul 17, 2018: IgE antibodies detected for the first time after kidney transplantation 23

Jun 12, 2018: CeMM: Protective Mechanism against Atherosclerosis Discovered 24

Apr 17, 2018: T cell antigen receptors act alone: longstanding immunological mystery solved 25

Mar 23, 2018: Breast cancer: new mechanism discovered for dissemination of metastatic tumour cells 27

Feb 20, 2018: Every experience that the brain perceives is unique 28

Nov 28, 2017: Two ERC Consolidator Grants for the MFPL 29

Nov 17, 2017: Diabetes drug helps repair UV-damaged DNA in cells of 'Moon children' 30

Nov 13, 2017: Children with epilepsy benefit from early surgery 31

Oct 30, 2017: HPV: Vaccination and test reduce cancer risk by more than 90% 33

Oct 20, 2017: Vienna researchers explore a new way of specific drug delivery using liposomes 34

Oct 19, 2017: Serotonin helps to promote liver regeneration following liver resection for liver cancer-but also supports early tumour regrowth 35

Oct 17, 2017: Possible approach discovered for treating Multiple Sclerosis 37

Sep 19, 2017: Tumor-infiltrating B Lymphocytes Promote Melanoma Progression and Resistance to Therapy 38

Aug 21, 2017: Immune system can be modulated by targeted manipulation of cell metabolism 39

Jul 24, 2017: Potential biomarker discovered to allow more precise classification of malignant brain tumours in children 40

Jul 18, 2017: Cause of chemoresistance in small cell lung cancer discovered 41

Product News 42

Sep 20, 2017: Characterization of a Slowly Proliferating Population of Melanoma Cells with High Metastatic Properties 42

Jul 11, 2018: New model for predicting deep vein thrombosis and pulmonary embolism in cancer patients 44

Jun 05, 2018: Immunoglobulin E as a promising new form of anti-cancer immunotherapy 45

Feb 14, 2018: European premiere: implantation of the first 3D-printed, Y-shaped tracheal stent 46

Feb 12, 2018: Supermicrosurgery helps to combat lymphoedema following tumour removal 47

Other Significant Developments 49

Sep 26, 2018: New inflammatory biomarker predicts elevated thrombosis risk in cancer patients 49

Oct 18, 2017: MedUni Vienna starts fund-raising for precision medicine 50

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51


List Of Figure

List of Figures

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Medical University of Vienna, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Medical University of Vienna, Pharmaceuticals & Healthcare, Key Facts 2

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Medical University of Vienna, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Medical University of Vienna, Deals By Therapy Area, 2012 to YTD 2018 9

Medical University of Vienna, Medical Devices Deals, 2012 to YTD 2018 10

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cyxone Partners with Medical University of Vienna 12

Imugene Enters Into Partnership with Medical University of Vienna 13

APEIRON Biologics Enters into Licensing Agreement with Molecular Biotechnology and Medical University of Vienna 14

MedUni Vienna Enters into Licensing Agreement with Accequa 15

Cyxone to Acquire T20K Patent Portfolio from Medical University of Vienna 16

Cyxone Acquires Cyclotide Patent Rights from MedUni Vienna and University Medical Center Freiburg 17

Medical University of Vienna, Key Competitors 18

Medical University of Vienna, Key Employees 19

Medical University of Vienna, Subsidiaries 20

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Medical University of Vienna, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Medical University of Vienna (MUV) is a medical research institute that offers educational services. The institute provides research and education services in the field of medical science. Its research services include project submission, clinical and preclinical studies, research funding, biobank and medical engineering, patenting, research documentation and others. MUV's courses include clinical research, gender medicine, health care management, interdisciplinary pain medicine, medical hypnosis, periodontology, toxicology, and dental hypnosis, among others. The institute's outpatient services include immunization services, genetic counseling, donation of bodies to research, forensic medicine, and others. It provides medical research in allergology, immunology, infectiology, oncology, neuroscience and psychiatric-psychosocial science, vacular medicine, and bildgebung. MUV is headquartered in Vienna, Austria.

Medical University of Vienna-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Medical University of Vienna, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Medical University of Vienna, Medical Devices Deals, 2012 to YTD 2018 10

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Medical University of Vienna, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Cyxone Partners with Medical University of Vienna 12

Imugene Enters Into Partnership with Medical University of Vienna 13

Licensing Agreements 14

APEIRON Biologics Enters into Licensing Agreement with Molecular Biotechnology and Medical University of Vienna 14

MedUni Vienna Enters into Licensing Agreement with Accequa 15

Asset Transactions 16

Cyxone to Acquire T20K Patent Portfolio from Medical University of Vienna 16

Cyxone Acquires Cyclotide Patent Rights from MedUni Vienna and University Medical Center Freiburg 17

Medical University of Vienna-Key Competitors 18

Medical University of Vienna-Key Employees 19

Medical University of Vienna-Locations And Subsidiaries 20

Head Office 20

Other Locations & Subsidiaries 20

Recent Developments 21

Strategy And Business Planning 21

Oct 19, 2017: Fresenius Vamed opens Institute for Gender Medicine 21

Government and Public Interest 22

Aug 28, 2018: Epigenetic analysis of aggressive brain tumors 22

Jul 17, 2018: IgE antibodies detected for the first time after kidney transplantation 23

Jun 12, 2018: CeMM: Protective Mechanism against Atherosclerosis Discovered 24

Apr 17, 2018: T cell antigen receptors act alone: longstanding immunological mystery solved 25

Mar 23, 2018: Breast cancer: new mechanism discovered for dissemination of metastatic tumour cells 27

Feb 20, 2018: Every experience that the brain perceives is unique 28

Nov 28, 2017: Two ERC Consolidator Grants for the MFPL 29

Nov 17, 2017: Diabetes drug helps repair UV-damaged DNA in cells of 'Moon children' 30

Nov 13, 2017: Children with epilepsy benefit from early surgery 31

Oct 30, 2017: HPV: Vaccination and test reduce cancer risk by more than 90% 33

Oct 20, 2017: Vienna researchers explore a new way of specific drug delivery using liposomes 34

Oct 19, 2017: Serotonin helps to promote liver regeneration following liver resection for liver cancer-but also supports early tumour regrowth 35

Oct 17, 2017: Possible approach discovered for treating Multiple Sclerosis 37

Sep 19, 2017: Tumor-infiltrating B Lymphocytes Promote Melanoma Progression and Resistance to Therapy 38

Aug 21, 2017: Immune system can be modulated by targeted manipulation of cell metabolism 39

Jul 24, 2017: Potential biomarker discovered to allow more precise classification of malignant brain tumours in children 40

Jul 18, 2017: Cause of chemoresistance in small cell lung cancer discovered 41

Product News 42

Sep 20, 2017: Characterization of a Slowly Proliferating Population of Melanoma Cells with High Metastatic Properties 42

Jul 11, 2018: New model for predicting deep vein thrombosis and pulmonary embolism in cancer patients 44

Jun 05, 2018: Immunoglobulin E as a promising new form of anti-cancer immunotherapy 45

Feb 14, 2018: European premiere: implantation of the first 3D-printed, Y-shaped tracheal stent 46

Feb 12, 2018: Supermicrosurgery helps to combat lymphoedema following tumour removal 47

Other Significant Developments 49

Sep 26, 2018: New inflammatory biomarker predicts elevated thrombosis risk in cancer patients 49

Oct 18, 2017: MedUni Vienna starts fund-raising for precision medicine 50

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51


List Of Figure

List of Figures

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Medical University of Vienna, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Medical University of Vienna, Pharmaceuticals & Healthcare, Key Facts 2

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Medical University of Vienna, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Medical University of Vienna, Deals By Therapy Area, 2012 to YTD 2018 9

Medical University of Vienna, Medical Devices Deals, 2012 to YTD 2018 10

Medical University of Vienna, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cyxone Partners with Medical University of Vienna 12

Imugene Enters Into Partnership with Medical University of Vienna 13

APEIRON Biologics Enters into Licensing Agreement with Molecular Biotechnology and Medical University of Vienna 14

MedUni Vienna Enters into Licensing Agreement with Accequa 15

Cyxone to Acquire T20K Patent Portfolio from Medical University of Vienna 16

Cyxone Acquires Cyclotide Patent Rights from MedUni Vienna and University Medical Center Freiburg 17

Medical University of Vienna, Key Competitors 18

Medical University of Vienna, Key Employees 19

Medical University of Vienna, Subsidiaries 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Medical University of Vienna, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.